Use your antibodies-online credentials, if available.
Keine Produkte auf Ihrer Vergleichsliste.
Ihr Warenkorb ist leer.
The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). Zusätzlich bieten wir Ihnen und viele weitere Produktgruppen zu diesem Protein an.
Showing 10 out of 48 products:
Human Polyclonal FANCF Primary Antibody für ELISA, WB - ABIN4310518
de Winter, Rooimans, van Der Weel, van Berkel, Alon, Bosnoyan-Collins, de Groot, Zhi, Waisfisz, Pronk, Arwert, Mathew, Scheper, Hoatlin, Buchwald, Joenje: The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. in Nature genetics 2000
LOH in FA genes appears to be a common feature of head and neck squamous cell carcinomas development seen here in 57% of patients and other mutation types may increase this mutation frequency. We suggest larger patient cohorts would be needed to test the observed association of LOH in FANCF and patient survival comprehensively
CpG island methylation of FANCF gene promoter region is strongly associated with the susceptibility and clinicopathologic features of epithelial ovarian cancer.
careful examination of three electively aborted fetuses in one family and one affected girl in the other indicated an association of the FANCF loss-of-function mutation with a severe phenotype characterized by multiple malformations
Using small interfering RNA (siRNA), knockdown of FANCF, FANCL (zeige FANCL Antikörper), or FANCD2 (zeige FANCD2 Antikörper) inhibited function of the FA/BRCA pathway in A549, A549/DDP (zeige TIMM8A Antikörper) and SK-MES (zeige ME1 Antikörper)-1 cells, and potentiated sensitivity of the three cells to cisplatin.
Data suggest that the Fanconi anemia group F protein/BRCA1/2 proteins pathway may be a new target to reverse adriamycin (ADR (zeige AKR1B1 Antikörper)) resistance in leukemia treatment.
Silencing of FANCF enhanced the antiproliferative effect of ADM (zeige ADM Antikörper) in OVCAR3 cells.
FANCF methylation is a rare event in Japanese primary invasive breast cancer.
Data identify the gene encoding Fanconi F (FANCF) as an ICSBP (zeige IRF8 Antikörper) target gene.
FANCF acts as a flexible adaptor protein that plays a key role in the proper assembly of the FA core complex.
results showed that FANCF methylation regulates the expression of FANCF at both mRNA and protein levels; methylation-induced inactivation of FANCF plays an important role in the occurrence of ovarian cancers via disrupting the FA-BRCA pathway
Our results suggest that FANCF suppresses ovarian tumourigenesis through its role in normal gonadal development, but also by maintaining genome stability
The Fanconi anemia complementation group (FANC) currently includes FANCA, FANCB, FANCC, FANCD1 (also called BRCA2), FANCD2, FANCE, FANCF, FANCG, FANCI, FANCJ (also called BRIP1), FANCL, FANCM and FANCN (also called PALB2). The previously defined group FANCH is the same as FANCA. Fanconi anemia is a genetically heterogeneous recessive disorder characterized by cytogenetic instability, hypersensitivity to DNA crosslinking agents, increased chromosomal breakage, and defective DNA repair. The members of the Fanconi anemia complementation group do not share sequence similarity; they are related by their assembly into a common nuclear protein complex. This gene encodes the protein for complementation group F.
Fanconi anemia protein
, Fanconi anemia group F protein
, Fanconi anemia, complementation group F
, fanconi anemia group F protein-like